Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Antti Siltanen

Analyst

Antti Siltanen portrait

Coverage

Herantis PharmaNexstimFaron PharmaceuticalsNightingale HealthBioretecAiforia TechnologiesBiohitOrionModulight

Latest content

ShowingAll content types

Aiforia H2'25: Green shoots on the clinical side

Research 2026-03-09 09:51 by Antti Siltanen
Aiforia Technologies

Nightingale H1'26: Research projects accelerate H2

Research 2026-03-06 10:44 by Antti Siltanen
Nightingale Health

Herantis H2'25: Secure financing and initiate new study

Research 2026-03-06 10:39 by Antti Siltanen
Herantis Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account

Faron H2'25: High stakes in financing success

Research 2026-03-05 09:33 by Antti Siltanen
Faron Pharmaceuticals

Aiforia H2'25 preview: Will customer wins turn into growth?

Analyst Comment 2026-03-04 08:01 by Antti Siltanen
Aiforia Technologies

Faron H2'25 preview: Funding the research program is the next endeavor

Analyst Comment 2026-03-03 08:15 by Antti Siltanen
Faron Pharmaceuticals

Faron and City of Hope plan new study

Analyst Comment 2026-03-03 08:18 by Antti Siltanen
Faron Pharmaceuticals

Nightingale H1'26 preview: Revenue still relies on research projects

Analyst Comment 2026-03-03 08:11 by Antti Siltanen
Nightingale Health

Herantis H2'25 preview: Blood-brain barrier passed and financial barriers lowered

Analyst Comment 2026-03-02 08:19 by Antti Siltanen
Herantis Pharma

Nexstim H2'25: Overvaluation corrected

Research 2026-02-27 08:51 by Antti Siltanen
Nexstim
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.